At Quanticate, we are delighted to have the opportunity to support Cancer Research UK with their new study DETERMINE (Determining Extended Therapeutic indications for Existing drugs in Rare Molecularly-defined Indications using a National Evaluation platform trial).
A novel umbrella-basket platform design is being used to evaluate the efficacy of licensed therapies for unlicensed indications of rare adult, paediatric and teenage/young adult tumours. The ultimate aim is to provide new treatment options for patients with rare malignancies.